Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -612568.11% is 49789% below its 2-year average of -1227.86%, near the low end of its 2-year range (-612568.11%–0.00%).
24844.45% below its 12-month average of -2455.73%.
Reported quarterly profit margin; no daily interpolation. Q3 FY2025 (2026-03-31): -12278.65%.
NET PROFIT MARGIN
-612568.11%
NET PROFIT MARGIN AVG TTM
-2455.73%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-24844.45%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 706 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Lunai Bioworks Inc.
Market Cap
$5.21M
Net Profit Margin
-612568.11%
TTM Avg
-2455.73%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.06M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1794.91%
5Y Avg
-2605.04%
Market Cap
$5.24M
Net Profit Margin
0.00%
TTM Avg
-61.23%
3Y Avg
-156.55%
5Y Avg
-194.88%
Market Cap
$5.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.26M
Net Profit Margin
-294.91%
TTM Avg
-320.57%
3Y Avg
-453.36%
5Y Avg
-361.46%
Market Cap
$5.29M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.05M
Net Profit Margin
-4011.86%
TTM Avg
-2005.93%
3Y Avg
-2671.67%
5Y Avg
-1781.12%
Market Cap
$5.01M
Net Profit Margin
-106.78%
TTM Avg
-43.08%
3Y Avg
-12.30%
5Y Avg
-12.30%
Market Cap
$4.82M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.21M | -612568.11% | -2455.73% | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.06M | 0.00% | 0.00% | -1794.91% | -2605.04% |
| Pulmatrix, Inc. (PULM)vs › | $5.24M | 0.00% | -61.23% | -156.55% | -194.88% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | -294.91% | -320.57% | -453.36% | -361.46% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.05M | -4011.86% | -2005.93% | -2671.67% | -1781.12% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | -106.78% | -43.08% | -12.30% | -12.30% |
| CalciMedica, Inc. (CALC)vs › | $4.82M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.77M | -3985.58% | -1467.13% | -2181.72% | -1717.85% |
Operating Margin
0.0%
Net Profit Margin
-612568.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | -12278.65% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |